Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Veritas In SilicoTSE:130A 13 9-Day RSI is 38.28 as of Aug. 01, 2026. GuruFocus rates TSE:130A with a GF Score™ of 13/100. The stock has 4 warning signs investors should review. Among 1,420 Biotechnology companies, Veritas In Silico ranks better than 60.35% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Veritas In Silico (TSE:130A) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Veritas In Silico 9-Day RSI Related Terms
TSE:130A vs VRTX, REGN, RVMD: 9-Day RSI Comparison
For the Biotechnology subindustry, Veritas In Silico's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veritas In Silico 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Veritas In Silico's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Veritas In Silico's 9-Day RSI falls into.
Veritas In Silico (TSE:130A) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veritas In Silico (TSE:130A) has a 9-Day RSI of 38.28 as of Aug. 01, 2026. According to the industry distribution chart, Veritas In Silico ranks #563 out of 1420 companies in the Biotechnology industry, placing it in the top 39.6%.
Is Veritas In Silico's 9-Day RSI too high?
Veritas In Silico's current 9-Day RSI is 38.28. The Biotechnology industry median 9-Day RSI is 41.82. Veritas In Silico's value of 38.28 is 8.5% below this industry median. Based on the distribution chart, Veritas In Silico ranks #563 out of 1420 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Veritas In Silico has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Veritas In Silico's 9-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Veritas In Silico ranks #563 out of 1420 companies for 9-Day RSI. This puts Veritas In Silico in the upper half of its industry. The industry median 9-Day RSI is 41.82. Veritas In Silico's value of 38.28 is 8.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 41.82, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Veritas In Silico's current 9-Day RSI of 38.28 is 8.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 41.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veritas In Silico's current 9-Day RSI is 38.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veritas In Silico stock overvalued right now?
Veritas In Silico (TSE:130A) has a current 9-Day RSI of 38.28. The current 9-Day RSI is 38.28 and 8.5% below the Biotechnology industry median of 41.82. Veritas In Silico's overall GF Score™ is 13/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Veritas In Silico (TSE:130A), the current 9-Day RSI is 38.28 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Veritas In Silico Inc is engaged in discovery of mRNA-targeted small molecule and antisense oligonucleotide drugs. It has ibVIS platform that combines informatics (i) and experimental biology at Veritas In Silico (VIS) that will bring to fruition mRNA-targeted drugs.
13GF Score
Get the complete analysis for TSE:130A
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:130A has been successfully added to your 
